

John N Waldron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2898186/publications.pdf>

Version: 2024-02-01

179
papers

9,396
citations

31902

53
h-index

43802

91
g-index

182
all docs

182
docs citations

182
times ranked

10383
citing authors

#	ARTICLE	IF	CITATIONS
1	Deintensification Candidate Subgroups in Human Papillomavirus-Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-550.	0.8	551
2	Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas. <i>Clinical Cancer Research</i> , 2010, 16, 1129-1139.	3.2	353
3	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus-Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	0.8	345
4	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6213-6221.	0.8	289
5	miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway. <i>Cancer Research</i> , 2011, 71, 2381-2391.	0.4	258
6	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. <i>Radiotherapy and Oncology</i> , 2018, 126, 3-24.	0.3	244
7	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. <i>Oral Oncology</i> , 2013, 49, 79-85.	0.8	239
8	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1221-1237.	5.1	226
9	Screening for depression in head and neck cancer. <i>Psycho-Oncology</i> , 2004, 13, 269-280.	1.0	225
10	Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 276-283.	0.4	207
11	External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. <i>Acta Oncologica</i> , 2015, 54, 1423-1429.	0.8	195
12	Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). <i>Journal of Clinical Oncology</i> , 2021, 39, 956-965.	0.8	195
13	T1/T2 Glottic Cancer Managed by External Beam Radiotherapy: The Influence of Pretreatment Hemoglobin on Local Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 347-353.	0.4	169
14	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012, 103, 49-56.	0.3	167
15	Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. <i>Cancer</i> , 2015, 121, 545-555.	2.0	133
16	Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. <i>International Journal of Cancer</i> , 2010, 126, 2036-2048.	2.3	126
17	Intraobserver and Interobserver Variability in GTV Delineation on FDG-PET-CT Images of Head and Neck Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 763-770.	0.4	121
18	Spinal cord ependymomas: a retrospective analysis of 59 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 27, 223-229.	0.4	111

#	ARTICLE	IF	CITATIONS
19	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. <i>Cancer</i> , 2015, 121, 294-301.	2.0	109
20	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. <i>British Journal of Radiology</i> , 2018, 91, 20170498.	1.0	109
21	Point-of-care outcome assessment in the cancer clinic: Audit of data quality. <i>Radiotherapy and Oncology</i> , 2010, 95, 339-343.	0.3	105
22	Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?. <i>Lung Cancer</i> , 2005, 49, 109-115.	0.9	100
23	Temporal Nodal Regression and Regional Control After Primary Radiation Therapy for N2-N3 Head-and-Neck Cancer Stratified by HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1078-1085.	0.4	100
24	Senescence, Necrosis, and Apoptosis Govern Circulating Cell-free DNA Release Kinetics. <i>Cell Reports</i> , 2020, 31, 107830.	2.9	100
25	Potentially Prognostic miRNAs in HPV-Associated Oropharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2154-2162.	3.2	99
26	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer</i> , 2017, 123, 3691-3700.	2.0	99
27	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 340-352.	0.4	99
28	A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 9-13.	0.4	93
29	Ethmoid Sinus Cancer: Twenty-nine Cases Managed With Primary Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 361-369.	0.4	91
30	Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. <i>Head and Neck</i> , 2012, 34, 1681-1703.	0.9	90
31	Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2570-2596.	0.8	88
32	Carcinoma of the maxillary antrum: a retrospective analysis of 110 cases. <i>Radiotherapy and Oncology</i> , 2000, 57, 167-173.	0.3	82
33	Significance of Dysregulated Metadherin and MicroRNA-375 in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7539-7550.	3.2	82
34	Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. <i>Head and Neck</i> , 2016, 38, E820-6.	0.9	82
35	Cognitive Functioning After Radiotherapy or Chemoradiotherapy for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 126-134.	0.4	78
36	Patterns of Care in Elderly Head-and-Neck Cancer Radiation Oncology Patients: A Single-Center Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 46-51.	0.4	77

#	ARTICLE	IF	CITATIONS
37	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 67, 174-182.	1.3	75
38	Lin28b Promotes Head and Neck Cancer Progression via Modulation of the Insulin-Like Growth Factor Survival Pathway. <i>Oncotarget</i> , 2012, 3, 1641-1652.	0.8	74
39	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2017, 7, 246-253.	1.1	73
40	Plasma redox imbalance caused by albumin oxidation promotes lung-predominant NETosis and pulmonary cancer metastasis. <i>Nature Communications</i> , 2018, 9, 5116.	5.8	72
41	Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status. <i>Head and Neck</i> , 2014, 36, 802-810.	0.9	69
42	Salvage surgery for locally recurrent oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E658-64.	0.9	66
43	A retrospective analysis of 52 cases of spinal cord glioma managed with radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 837-842.	0.4	64
44	Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2007, 85, 7-16.	0.3	64
45	Prevalence and nature of survivorship needs in patients with head and neck cancer. <i>Head and Neck</i> , 2016, 38, 1097-1103.	0.9	64
46	Body mass index and prognosis in patients with head and neck cancer. <i>Head and Neck</i> , 2017, 39, 1226-1233.	0.9	64
47	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 220.	3.4	64
48	Cone-Beam CT Assessment of Interfraction and Intrafraction Setup Error of Two Head-and-Neck Cancer Thermoplastic Masks. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 949-955.	0.4	63
49	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 159-169.	0.4	61
50	Preoperative Radiotherapy for Adult Head and Neck Soft Tissue Sarcoma: Assessment of Wound Complication Rates and Cancer Outcome in a Prospective Series. <i>World Journal of Surgery</i> , 2003, 27, 875-883.	0.8	59
51	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 2552-2557.	0.8	58
52	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1107-1116.	0.4	57
53	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. <i>Oral Oncology</i> , 2016, 54, 75-80.	0.8	56
54	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	3.0	56

#	ARTICLE	IF	CITATIONS
55	Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1403-1407.	0.4	55
56	Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 490-499.	1.1	55
57	Potentially Novel Candidate Biomarkers for Head and Neck Squamous Cell Carcinoma Identified Using an Integrated Cell Line-based Discovery Strategy. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1404-1415.	2.5	55
58	A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. <i>Cancer</i> , 2001, 92, 1484-1494.	2.0	54
59	Tumor-Na ⁺ ve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4230-4244.	3.2	53
60	Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. <i>Cancer</i> , 2013, 119, 2701-2709.	2.0	51
61	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1017-1027.	0.4	50
62	Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. <i>Oncotarget</i> , 2015, 6, 4537-4550.	0.8	50
63	Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure. <i>Oral Oncology</i> , 2013, 49, 255-260.	0.8	49
64	Retrospective Study of Palliative Radiotherapy in Newly Diagnosed Head and Neck Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 958-963.	0.4	48
65	Paranasal Sinus Cancer: Caveats and Controversies. <i>World Journal of Surgery</i> , 2003, 27, 849-855.	0.8	46
66	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. <i>Scientific Reports</i> , 2020, 10, 4542.	1.6	46
67	Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2003, 68, 153-161.	0.3	45
68	Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 4078-4090.	0.8	45
69	The prevalence and determinants of return to work in head and neck cancer survivors. <i>Supportive Care in Cancer</i> , 2019, 27, 539-546.	1.0	45
70	Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. <i>Radiotherapy and Oncology</i> , 2002, 63, 269-274.	0.3	44
71	Carcinoma-in-situ of the glottic larynx: results of treatment with radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 1235-1238.	0.4	42
72	The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. <i>Cancer Epidemiology</i> , 2013, 37, 820-829.	0.8	42

#	ARTICLE	IF	CITATIONS
73	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	2.0	42
74	Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: Quality of life in a prospective phase I/II trial. <i>Radiotherapy and Oncology</i> , 2008, 87, 181-187.	0.3	40
75	Truths and Myths About Radiotherapy for Verrucous Carcinoma of Larynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1110-1115.	0.4	39
76	Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival. <i>Clinical Cancer Research</i> , 2012, 18, 196-206.	3.2	39
77	Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. <i>Head and Neck</i> , 2016, 38, E1102-9.	0.9	39
78	Results of radiotherapy for primary subglottic squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1245-1250.	0.4	38
79	Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 363-373.	0.4	38
80	A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 131, 179-185.	0.3	38
81	Targeting Polo-Like Kinase 1 Enhances Radiation Efficacy for Head-and-Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 253-260.	0.4	37
82	Morphologic and topographic radiologic features of human papillomavirus-related and "unrelated" oropharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 1524-1534.	0.9	37
83	Efficacy of Combining GMX1777 with Radiation Therapy for Human Head and Neck Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 898-911.	3.2	36
84	Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. <i>Oral Oncology</i> , 2013, 49, 407-412.	0.8	36
85	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	1.1	36
86	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 225-231.	0.3	33
87	Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. <i>Head and Neck</i> , 2015, 37, 655-661.	0.9	30
88	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.3	30
89	Considerations for head and neck oncology practices during the coronavirus disease 2019 (COVID -19) pandemic: Wuhan and Toronto experience. <i>Head and Neck</i> , 2020, 42, 1202-1208.	0.9	30
90	Clinical outcomes in patients with T4 laryngeal cancer treated with primary radiotherapy versus primary laryngectomy. <i>Head and Neck</i> , 2016, 38, E2035-40.	0.9	29

#	ARTICLE	IF	CITATIONS
91	Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1127-1136.	0.4	28
92	A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 173-180.	0.3	28
93	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 186-195.	0.4	27
94	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 71-79.	1.2	26
95	Lack of influence of intravenous contrast on head and neck IMRT dose distributions. <i>Acta Oncologica</i> , 2008, 47, 90-94.	0.8	25
96	Sebaceous gland carcinoma of the head and neck: The Princess Margaret Hospital experience. <i>Head and Neck</i> , 2013, 35, 316-320.	0.9	25
97	¹⁸ F-FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A meta-analysis of reported studies. <i>Head and Neck</i> , 2019, 41, 551-561.	0.9	24
98	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. <i>Radiotherapy and Oncology</i> , 2021, 154, 70-75.	0.3	23
99	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.3	22
100	Wound healing morbidity in STS patients treated with preoperative radiotherapy in relation to in vitro skin fibroblast radiosensitivity, proliferative capacity and TGF- β 2 activity. <i>Radiotherapy and Oncology</i> , 2006, 78, 17-26.	0.3	20
101	Radiation Therapy for Head and Neck Cancers. <i>Seminars in Oncology Nursing</i> , 2009, 25, 193-202.	0.7	20
102	The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. <i>Supportive Care in Cancer</i> , 2011, 19, 1175-1182.	1.0	20
103	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 1208.	1.2	20
104	Integrated Omic Analysis of Oropharyngeal Carcinomas Reveals Human Papillomavirus (HPV)-dependent Regulation of the Activator Protein 1 (AP-1) Pathway. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3572-3584.	2.5	19
105	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 858-867.	0.4	19
106	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 368.	1.2	19
107	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021, 124, 1543-1551.	2.9	19
108	Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). <i>European Journal of Cancer</i> , 2017, 72, 192-199.	1.3	18

#	ARTICLE	IF	CITATIONS
109	Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 521-529.	0.4	17
110	Partial Laryngeal IMRT for T2N0 Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 941-949.	0.4	17
111	Treatment implications of postoperative chemoradiotherapy for squamous cell carcinoma of the oral cavity with minor and major extranodal extension. <i>Oral Oncology</i> , 2020, 110, 104845.	0.8	17
112	Surgical salvage after failed radiation for paranasal sinus malignancy. <i>Laryngoscope</i> , 1998, 108, 1618-1622.	1.1	16
113	Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers. <i>Cancer Medicine</i> , 2014, 3, 426-433.	1.3	16
114	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , 2016, 59, 43-49.	0.8	16
115	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 17-26.	1.0	16
116	Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers. <i>Cancer</i> , 2012, 118, 1554-1565.	2.0	15
117	Outcome following radiotherapy for head and neck basal cell carcinoma with "aggressive" features. <i>Oral Oncology</i> , 2017, 72, 157-164.	0.8	15
118	The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 134-145.	0.4	15
119	Longer survival in patients with human papillomavirus-related head and neck cancer after positive postradiation planned neck dissection. <i>Head and Neck</i> , 2015, 37, 946-952.	0.9	14
120	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	1.3	14
121	Brachytherapy patient safety events in an academic radiation medicine program. <i>Brachytherapy</i> , 2018, 17, 16-23.	0.2	13
122	Patterns of failure and histopathologic outcome predictors following definitive radiotherapy and planned neck dissection with residual disease. <i>Head and Neck</i> , 2012, 34, 913-922.	0.9	12
123	Partner's survivorship care needs: An analysis in head and neck cancer patients. <i>Oral Oncology</i> , 2017, 71, 113-121.	0.8	12
124	Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e98557.	1.1	11
125	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. <i>Oral Oncology</i> , 2021, 114, 105167.	0.8	11
126	Medial Mandibulotomies: Is there sufficient space in the midline to allow a mandibulotomy without compromising the dentition?. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2013, 42, 32.	0.9	10

#	ARTICLE	IF	CITATIONS
127	Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. <i>Cancer</i> , 2022, 128, 2908-2921.	2.0	10
128	Clonogenic survival and cytokinesis-blocked binucleation of skin fibroblasts and normal tissue complications in soft tissue sarcoma patients treated with preoperative radiotherapy. <i>Radiotherapy and Oncology</i> , 2004, 72, 103-112.	0.3	9
129	Indications and Outcomes of Radiation Therapy for Skin Cancer of the Head and Neck. <i>Clinics in Plastic Surgery</i> , 2009, 36, 335-344.	0.7	9
130	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016, 34, 575-583.	1.2	9
131	Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma. <i>Oral Oncology</i> , 2018, 82, 162-167.	0.8	9
132	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. <i>Laryngoscope</i> , 2021, 131, E1162-E1171.	1.1	9
133	Importance of Margins, Radiotherapy, and Systemic Therapy in Mucosal Melanoma of the Head and Neck. <i>Laryngoscope</i> , 2021, 131, 2269-2276.	1.1	9
134	Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 10-16.	0.3	8
135	Tracheoesophageal voice prosthesis management in laryngectomy patients during the COVID-19 pandemic. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2020, 49, 59.	0.9	8
136	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	0.8	8
137	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. <i>International Journal of Cancer</i> , 2022, 150, 1329-1340.	2.3	8
138	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (âˆ“) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6020-6020.	0.8	7
139	CCTG HN.10: A phase II single-arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma (NCT03822897).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6592-TPS6592.	0.8	7
140	Spiradenocarcinoma Arising from a Spiradenocylindroma: Unusual Case with Lymphoepithelioma-Like Areas. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, 215-220.	0.6	6
141	Outcome following IMRT for T2 glottic cancer: the potential impact of image-guidance protocols on local control. <i>Journal of Radiation Oncology</i> , 2014, 3, 267-275.	0.7	6
142	Extra-pulmonary small cell carcinoma in the head and neck setting: The role of prophylactic cranial irradiation. <i>Oral Oncology</i> , 2015, 51, e57-e59.	0.8	5
143	The Challenges of Treatment Adaptation and De-intensification in Human Papillomavirus-Positive Oropharyngeal Cancer: The Difficult Journey Back. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 18-20.	0.4	5
144	Clinical outcomes of hypofractionated radiation therapy for choroidal metastases: Symptom palliation, tumor control, and survival. <i>Practical Radiation Oncology</i> , 2017, 7, 388-395.	1.1	5

#	ARTICLE	IF	CITATIONS
145	Presence and duration of feeding tube in a 5-year cohort of patients with head and neck cancer treated with curative intensity-modulated radiation therapy. <i>Head and Neck</i> , 2021, 43, 1610-1620.	0.9	5
146	Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey. <i>Oral Oncology</i> , 2021, 114, 105165.	0.8	5
147	A cost-utility analysis comparing CT surveillance, PET-CT surveillance, and planned postradiation neck dissection for advanced nodal HPV-positive oropharyngeal cancer. <i>Cancer</i> , 2021, 127, 3372-3380.	2.0	5
148	Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma. <i>Oral Oncology</i> , 2022, 125, 105716.	0.8	5
149	Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up. <i>Cancers</i> , 2022, 14, 3105.	1.7	5
150	A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways. <i>Cancer Epidemiology</i> , 2016, 42, 173-180.	0.8	4
151	Sexual satisfaction in nasopharyngeal carcinoma survivors: Rates and determinants. <i>Oral Oncology</i> , 2020, 109, 104865.	0.8	4
152	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 255-262.	0.3	4
153	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 3640.	1.7	4
154	Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. <i>Oral Oncology</i> , 2021, 120, 105419.	0.8	4
155	Fluorodeoxyglucose Positron Emission Tomography for the Preoperative Staging of Oral Cavity Cancers: Only One Piece of the Puzzle. <i>Journal of Clinical Oncology</i> , 2006, 24, 4367-4368.	0.8	3
156	18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6563-6563.	0.8	3
157	Quantifying Neck Fibrosis and Its Functional Implications: Development of the Neck Fibrosis Scale. <i>Laryngoscope</i> , 2021, , .	1.1	3
158	Radiologic-pathologic correlation of major versus minor extranodal extension in oral cavity cancer. <i>Head and Neck</i> , 2022, 44, 1422-1429.	0.9	3
159	In response to Drs. Momm and Lutterbach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 969-970.	0.4	2
160	Technical challenges of sparing infrahyoid swallowing organs at risk in oropharynx squamous cell cancer treated with IMRT. <i>Medical Dosimetry</i> , 2014, 39, 146-151.	0.4	2
161	Cancer patients' acceptability of incorporating an epidemiology questionnaire within a clinical trial. <i>Clinical Trials</i> , 2015, 12, 237-245.	0.7	2
162	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , 2019, 97, 124-130.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 95-101.	0.3	2
164	Elective neck dissection versus positron emission tomographyâ€“computed tomographyâ€“guided management of the neck in clinically nodeâ€“negative early oral cavity cancer: A costâ€“utility analysis. <i>Cancer</i> , 2021, 127, 1993-2002.	2.0	2
165	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS5600-TPS5600.	0.8	2
166	Transoral robotic surgery (TORS)-guided radiotherapy (RT) volume de-intensification in p16-positive unknown primary squamous cell carcinoma (SCC) of the neck: A phase 2 trial (FIND).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6067-6067.	0.8	2
167	1041 A bilateral arc technique with distribution shaping in three dimensions, for treating tumors of the nasopharynx extending into the parapharyngeal spaces. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 236.	0.4	1
168	The Effect of Registration Volume Extent on Residual Errors Assessed Using Cone-Beam Computed Tomography in Radiation Treatment of Head and Neck Cancer. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2012, 43, 95-102.	0.2	1
169	Response to Letter to the Editor with Reference to article â€œPostoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failureâ€œ. <i>Oral Oncology</i> , 2013, 49, e19.	0.8	1
170	Reply to J.J. Beitler et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3218-3219.	0.8	1
171	Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinomaâ€“Reply. <i>JAMA Oncology</i> , 2017, 3, 125.	3.4	1
172	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 69-76.	0.9	1
173	Shortâ€“term and longâ€“term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. <i>Head and Neck</i> , 2021, 43, 456-466.	0.9	1
174	Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6085-6085.	0.8	1
175	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, , .	1.2	1
176	No evidence for improved TORS post-treatment feeding tube dependency rate relative to standard therapy in early stage oropharyngeal cancer. <i>Oral Oncology</i> , 2015, 51, e67.	0.8	0
177	Preoperative Radiation Therapy for Locally Advanced Sinus Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 763-764.	0.4	0
178	Osteoradionecrosis in head and neck cancer patients: Risk factors and comparison of grading systems.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18057-e18057.	0.8	0
179	Prognostic factors in sinonasal cancers: A multicenter pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6092-6092.	0.8	0